Significant Shareholder Update - BrokerBank Securities

Sep 09, 2015, 09:10 ET from BrokerBank Securities, Inc.

NEW YORK, Sept. 9, 2015 /PRNewswire/ -- Shareholders of Amicus Therapeutics, Inc. (NASDAQ: FOLD) have been rewarded in the month of September. The stock has appreciated over twenty percent in the last five trading sessions and an outstanding three hundred percent in the last year.

Investors may want to read the following critical information that includes insider ownership's recent activity, highlights of recent acquisition and analyst ratings.

Copy and paste to browser may be required.

About Amicus Therapeutics

Amicus Therapeutics is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS I.


This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.  


Content is researched, written and reviewed on a best-effort basis. This release and report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this release have not been compensated in any form by any source. A full disclaimer can be found by viewing due diligence. We are only human and may make mistakes. If you notice any errors or omissions, please notify us below.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.